Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.

BACKGROUND Patients with Birt-Hogg-Dubé (BHD) syndrome harbor germline mutations in the BHD tumor suppressor gene that are associated with an increased risk for kidney cancer. BHD encodes folliculin, a protein that may interact with the energy- and nutrient-sensing 5'-AMP-activated protein kinase-mammalian target of rapamycin (AMPK-mTOR) signaling pathways. METHODS We used recombineering methods to generate mice with a conditional BHD allele and introduced the cadherin 16 (KSP)-Cre transgene to target BHD inactivation to the kidney. Kidney cell proliferation was measured by BrdU incorporation and phospho-histone H3 staining. Kidney weight data were analyzed with Wilcoxon's rank-sum, Student's t, and Welch's t tests. Hematoxylin and eosin staining and immunoblot analysis and immunohistochemistry of cell cycle and signaling proteins were performed on mouse kidney cells and tissues. BHD knockout mice and kidney cells isolated from BHD knockout and control mice were treated with the mTOR inhibitor rapamycin. Mouse survival was evaluated by Kaplan-Meier analyses. All statistical tests were two-sided. RESULTS BHD knockout mice developed enlarged polycystic kidneys and died from renal failure by 3 weeks of age. Targeted BHD knockout led to the activation of Raf-extracellular signal-regulated protein kinase (Erk)1/2 and Akt-mTOR pathways in the kidneys and increased expression of cell cycle proteins and cell proliferation. Rapamycin-treated BHD knockout mice had smaller kidneys than buffer-treated BHD knockout mice had (n = 4-6 mice per group, relative kidney/body weight ratios, mean = 4.64% vs 12.2%, difference = 7.6%, 95% confidence interval = 5.2% to 10.0%; P < .001) and longer median survival time (n = 4-5 mice per group, 41.5 vs 23 days; P = .0065 ). CONCLUSIONS Homozygous loss of BHD may initiate renal tumorigenesis in the mouse. The conditional BHD knockout mouse may be a useful research model for dissecting multistep kidney carcinogenesis, and rapamycin may be considered as a potential treatment for Birt-Hogg-Dubé syndrome.

[1]  E. Henske,et al.  The Birt-Hogg-Dube and Tuberous Sclerosis Complex Homologs Have Opposing Roles in Amino Acid Homeostasis in Schizosaccharomyces pombe* , 2007, Journal of Biological Chemistry.

[2]  B. Shroot.  Great expectations--SID and industry relationship: a 20-year perspective. , 2007, The Journal of investigative dermatology.

[3]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[4]  Y. Nagashima,et al.  Identification and characterization of Birt–Hogg–Dubé associated renal carcinoma , 2007, The Journal of pathology.

[5]  E. Friedman,et al.  Cancer risks among BRCA1 and BRCA2 mutation carriers , 2007, British Journal of Cancer.

[6]  J. Hartley,et al.  Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling , 2006, Proceedings of the National Academy of Sciences.

[7]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[8]  L. Schmidt,et al.  Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis , 2006, Laboratory Investigation.

[9]  N. Sonenberg,et al.  mTOR signaling: implications for cancer and anticancer therapy , 2005, British Journal of Cancer.

[10]  D. Kwiatkowski,et al.  Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.

[11]  P. Igarashi,et al.  Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. , 2005, The Journal of clinical investigation.

[12]  W. Linehan,et al.  High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. , 2005, Journal of the National Cancer Institute.

[13]  Peter L Choyke,et al.  Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. , 2005, American journal of human genetics.

[14]  Peter Choyke,et al.  Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. , 2005, The Journal of urology.

[15]  Y. Tao,et al.  Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. , 2004, Journal of the American Society of Nephrology : JASN.

[16]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[17]  R. DePinho,et al.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. , 2004, Genes & development.

[18]  L. Schmidt,et al.  A germ-line insertion in the Birt–Hogg–Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Maquat.  Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics , 2004, Nature Reviews Molecular Cell Biology.

[20]  E. Kirkness,et al.  A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. , 2003, Human molecular genetics.

[21]  P. Kaldis,et al.  Cdk2 Knockout Mice Are Viable , 2003, Current Biology.

[22]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[23]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[24]  S. Richard,et al.  Clinical and genetic studies of Birt-Hogg-Dubé syndrome , 2002, Journal of medical genetics.

[25]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[26]  P. Igarashi,et al.  Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  P. Igarashi,et al.  A minimal Ksp-cadherin promoter linked to a green fluorescent protein reporter gene exhibits tissue-specific expression in the developing kidney and genitourinary tract. , 2002, Journal of the American Society of Nephrology : JASN.

[28]  P. Choyke,et al.  Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  O. Hino,et al.  A Novel Renal Carcinoma Predisposing Gene of the Nihon Rat Maps on Chromosome 10 , 2001, Japanese journal of cancer research : Gann.

[30]  Nancy A. Jenkins,et al.  Recombineering: a powerful new tool for mouse functional genomics , 2001, Nature Reviews Genetics.

[31]  D. Court,et al.  A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. , 2001, Genomics.

[32]  D. Brown,et al.  Potassium depletion increases proton pump (H(+)-ATPase) activity in intercalated cells of cortical collecting duct. , 2000, American journal of physiology. Renal physiology.

[33]  P. Igarashi,et al.  Uncompensated polyuria in a mouse model of Bartter's syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Zbar,et al.  Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. , 1999, Archives of dermatology.

[35]  L. Satlin,et al.  Developmental expression of ROMK in rat kidney. , 1999, American journal of physiology. Renal physiology.

[36]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[37]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[38]  S. Störkel,et al.  The human chromophobe cell renal carcinoma: Its probable relation to intercalated cells of the collecting duct , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.

[39]  L. Moe,et al.  Hereditary Multifocal Renal Cystadenocarcinomas and Nodular Dermatofibrosis in the German Shepherd Dog: Macroscopic and Histopathologic Changes , 1985, Veterinary pathology.

[40]  W. J. Dubé,et al.  Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. , 1977, Archives of dermatology.

[41]  P. Postmus,et al.  Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. , 2008, The Journal of investigative dermatology.

[42]  E. Henske,et al.  Activation of the mTOR signaling pathway in renal clear cell carcinoma. , 2007, The Journal of urology.

[43]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.

[44]  G. Martin,et al.  Analysis of Fgf8 gene function in vertebrate development. , 1997, Cold Spring Harbor symposia on quantitative biology.

[45]  S. Störkel,et al.  Intercalated cells as a probable source for the development of renal oncocytoma , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.